Pegfilgrastim On-Pro (Neulasta® On-Pro On Body Injector)

OncoLink Team
Last Modified: October 9, 2017

Pronounced: peg-fil-GRAS-tim

Classification: Colony Stimulating Factor

About Pegfilgrastim On-Pro (Neulasta® On-Pro On Body Injector)

Pegfilgrastim is a type of colony stimulating factor, which is a group of medications that stimulate the production and function of blood cells, including white blood cells, red blood cells and platelets. Granulocyte colony-stimulating factor (G-CSF) is a protein produced by the body to increase production of white blood cells. Pegfilgrastim is a long-acting, man-made version of G-CSF that stimulates white blood cell production, and in particular, neutrophil production. A neutrophil is a type of white blood cell that is responsible for fighting infection and is often decreased during cancer therapy. When the number of these cells drops below 1000/mm3, it is called neutropenia and puts the patient at significant risk of infection. Pegfilgrastim is used to prevent or treat neutropenia related to chemotherapy.

Pegfilgrastim is not a cancer treatment, but a supportive care medicine. This means it is used to lessen the bone marrow suppression (reduced blood counts) secondary to cancer and its cytotoxic treatments.

How to Take Pegfilgrastim

This formulation of Pegfilgrastim is delivered through an on-body injector, which is applied the same day you receive chemotherapy. The on-body injector will be applied and filled by your healthcare provider after you receive your chemotherapy. The on-body injector then delivers the pegfilgrastim dose the next day. You should also keep the injector on for 3 hours after the dose is delivered. There are several other precautions you need to follow when using the on-body injector:

  • Avoid traveling, driving or operating heavy machinery during hours 26-29 after the on-body injector is applied.
  • This on-body injector uses an acrylic adhesive. Be sure to report any allergy to acrylic adhesives to your healthcare team before utilizing the on-body injector.
  • Avoid MRI, X-ray, CT-Scan, Ultrasound and oxygen rich environments such as hyperbaric chambers while wearing the on-body injector
  • Avoid airport X-ray scans: request a manual pat down. Alert the TSA agent to exercise caution during the pat town to prevent accidental removal.
  • Keep the on-body injector 4 inches or more away from electrical equipment such as cell phones, cordless phones, microwaves and other appliances.
  • Avoid hot tubs, whirlpools, saunas, and direct sunlight while wearing the on-body device.
  • Do not use body lotion, creams, oils and skin cleansing products near the on-body injector.
  • Keep the on body injector dry for at least three hours prior to the scheduled administration of pegfilgrastim.

Storage and Handling

Do not reuse single dose vials, syringes or needles. Do not throw the vials, syringes, or needles in the household trash. Dispose of all used needles and syringes in a puncture-proof disposable container with a lid. The FDA provides further information about the disposal of vials, syringes and needles. Keep the vials out of the reach of children.

Possible Side Effects of Pegfilgrastim

There are a number of things you can do to manage the side effects of pegfilgrastim. Talk to your care team about these recommendations. They can help you decide what will work best for you. These are some of the most common or important side effects:

Bone or Muscle Pain

Pegfilgrastim stimulates the bone marrow to produce many white blood cells, which can lead to pain in the bones. This pain is often felt in the bones or muscles of the thighs, hips and upper arms. Your healthcare team may not want you to take acetaminophen (Tylenol®) because it can "mask" a fever, so talk to them about what pain relievers you can take.

Irritation or Burning at the Injection Site

Some people experience redness, swelling, or itching at the site of injection. This is usually temporary. The injection is known to sting or burn if given when it is cold. Take the medication out of the refrigerator 30 minutes ahead of time to allow it to come up to room temperature before administration.

Allergic Reactions

In some cases, patients can have an allergic reaction to this medication. Signs of a reaction can include: shortness of breath or difficulty breathing, chest pain, rash, flushing or itching or a decrease in blood pressure. If you notice any changes in how you feel during the injection, let your nurse know immediately.

Less common but important side effects can include:

  • Rupture of the spleen: Your healthcare team will monitor you for an enlarged spleen or rupture while using this medication. If you have pain in the left side of your abdomen or shoulder pain after receiving pegfilgrastim, notify your healthcare team immediately.
  • Acute Respiratory Distress Syndrome(ARDS)/Alveolar Hemmorage: This medication can cause a series lung problems called acute respiratory distress syndrome. If you experience shortness of breath, fever, breathing trouble or a fast rate of breathing, contact your healthcare team or go to the emergency room.
  • Capillary Leak Syndrome: Capillary leak syndrome is a condition in which blood, and components of blood, leak out of vessels and into body cavities and muscles. The movement of this fluid out of the vessels can cause hypotension (low blood pressure) and organ failure.  Signs and symptoms of capillary leak syndrome include: a sudden drop in blood pressure, weakness, fatigue, sudden swelling of the arms, legs or other parts of the body, nausea, and lightheadedness. If you are having any of these symptoms notify your healthcare provider immediately.
  • Kidney Problems: Pegfilgrastim can cause a decrease in kidney function or damage to the kidney. For this reason, your healthcare team will monitor your kidney function with blood tests while taking pegfilgrastim. Some patients will need to stop the medication due to kidney function changes. Notify your provider if you notice any blood in your urine, decrease in urination or darkening of the urine.
  • Sickle Cell Crisis: In patients with sickle cell anemia, pegfilgrastim can cause a sickle cell crisis. Contact your healthcare team immediately if you have symptoms of a sickle cell crisis including pain and trouble breathing.

Reproductive Concerns

Exposure of an unborn child to this medication could cause birth defects, so you should not become pregnant or father a child while on this medication. Effective birth control is necessary during treatment. Even if your menstrual cycle stops or you believe you are not producing sperm, you could still be fertile and conceive. You should consult with your healthcare team before breastfeeding while receiving this medication.

Keywords

Click on any of these terms for more related articles

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
R
S
T
U
V
X
Y
Z
#
 
A
B
C
E
F
G
H
K
L
M
N
O
P
R
S
T
U
V
 
 
Stay informed with the latest information from OncoLink!   Subscribe to OncoLink eNews
View our newsletter archives